Chemotherapy-induced Cardiac Dysfunction: How to Prevent It?


Prof Dr Geetha Subramanian, Varanasi    06 January 2018

  1. Choose chemotherapy doses with less risk of cardiotoxicity.
  2. Accumulative dose and the schedule of chemotherapy are important factors for cardiotoxicity.
  3. Prepare chemotherapy with a lower potential cardiotoxicity effect, for instance in anthracyclines with continuous infusions or altered delivery systems (i.e., Liposomal doxorubicin).
  4. Try to detect and properly control CV risk factors.
  5. Start CV treatment with an ACEI (or ARB) and a β-blocker in high-risk patients or in patients with low normal heart function, as well as in patients with a reduced or recovered ejection fraction.
  6. Dexrazoxane has been shown to prevent LVEF in patients treated with doxorubicin, and should be considered in high-risk patients.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.